title: Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid: Balancing the Risks for Male Allograft Recipients.
authors.affiliation: 1 Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium. 2 Department of Gynecology and Obstetrics, University Hospitals Leuven, Belgium.
authors.forename: Dirk R J
authors.initials: DR
authors.lastname: Kuypers
authors.forename: Tim
authors.initials: T
authors.lastname: Van Mieghem
authors.forename: Björn
authors.initials: B
authors.lastname: Meijers
authors.forename: Kathleen
authors.initials: K
authors.lastname: Claes
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D064591:Allografts; D003257:Consumer Product Safety; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D005260:Female; D006077:Government Agencies / Q000331:legislation & jurisprudence*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D009173:Mycophenolic Acid / Q000009:adverse effects*; D016377:Organ Transplantation / Q000009:adverse effects / Q000379:methods*; D061214:Patient Safety; D011247:Pregnancy; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid